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Abstract  
 
Background: The present study evaluated the role of the CB2r in the regulation of depressive-like 
behaviors. To this aim, transgenic mice overexpressing the CB2r (CB2xP) were challenged against 
different types of acute and chronic experimental paradigms to evaluate its response to depressive-
like behaviors.    
Methods: Tail suspension (TST), novelty suppressed feeding (NSFT) and unpredictable chronic mild 
stress tests (CMS) were carried out in CB2xP. Furthermore, acute and chronic antidepressant-like 
effects of the CB2r antagonist AM630 were evaluated (forced swimming test (FST) and CMS, 
respectively) in WT mice. 
Results: Overexpression of the CB2r resulted in decreased depressive-like behaviors in TST and 
NSFT. CMS failed to produce any alteration in the CB2xP in TST and sucrose consumption. In 
addition, no changes were observed in BDNF gene and protein expressions in stressed-CB2xP mice. 
Interestingly, the administration of AM630 (1 and 3 mg/kg, i.p.) decreased the emotional-behavior 
response to acute anxiety-stimuli (FST) in WT mice. Repeated administration of AM630 for 4 weeks (1 
mg/kg; twice a day; i.p.) blocked the effects of CMS on TST, sucrose intake, BDNF gene and protein 
expressions. 
Conclusions: Taken together, these results suggest that increased expression of the CB2r 
significantly reduced depressive-related behaviors and point out the CB2r as a new potential key 
target in the treatment of depression related disorders. 
 
 
 
 
 
 
 
Key words: cannabinoid CB2 receptor, depression, antidepressant, brain-derived neurotrophic factor, 
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1. INTRODUCTION 
 
The limited efficacy of current antidepressant treatments requires the development of alternative 
drugs. Recent pharmacological and genetic findings revealed the endocannabinoid system as a target 
closely related with the regulation of mood disorders. In fact, cannabinoid CB1 antagonists, 
SR141716A (rimonabant) and AM251, have presented antidepressant-like effects in animals models 
of depression (1-4). In addition, 5-HT, NA and dopamine levels in the prefrontal cortex increased after 
the administration of rimonabant (1;2;4;5). However, paradoxically rimonabant has been linked to 
increased risk of anxiety, depression and suicidal thoughts (6;7) in the treatment of depressive 
disorders in humans. Cannabinoid CB1 agonists and fatty acid amide hydrolase (FAAH) inhibitors 
induce antidepressant-like effects in the forced swimming test in rats (8)  providing further support of a 
pivotal role of the endocannabinoid system in the pathogenesis of depression. Chronic treatment with 
these drugs promoted neurogenesis in hippocampus and enhanced central serotoninergic and 
noradrenergic transmission (9). In addition, different animal models of depression revealed significant 
increases in CB1r density and function at the prefrontal cortex (10;11) that may be reversed by chronic 
fluoxetine treatment (10).  Clinically, significant up-regulation of CB1r density and CB1r-stimulated G-
protein activation was found in the prefrontal cortex of depressive suicide victims (12). 
Initially, CB2r was identified in the brain only under pathological conditions such as senile plaques 
in Alzheimer’s disease (13), in activated microglial cells/macrophages of multiple sclerosis (24), 
amyotrophic lateral sclerosis spinal cord (14) and near to tumors (15;16). Recently, CB2r were found 
under normal conditions in the brainstem of rat, mouse and ferret (17). Further studies in the rat 
identified a wide distribution of CB2r in different brain areas including spinal nucleus, hippocampus, 
olfactory nucleus, cerebral cortex, amygdala, striatum, thalamus and cerebellum (18;19).  The 
presence of CB2r in these areas suggests its potential role in the regulation of anxiety and depression.  
Interestingly, a reduction of CB2r in striatum, midbrain and hippocampus was reported in animal 
models of depression (20). Conversely, intracerebroventricular microinjection of cannabinoid CB2 
antisense oligonucleotide induced anxiolytic-like effects (21). In addition, an association between 
cannabinoid CB2r polymorphism Q63R was also detected in Japanese depressed and alcoholic 
subjects (20).   
The responses of transgenic mice overexpressing this receptor (CB2xP) to acute and chronic 
anxiogenic-like stimuli were studied.  The acute (the forced swimming test) and chronic (CMS 
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procedure) effects of AM630 were evaluated. Furthermore, the influence of CB2r on hippocampal 
neurogenesis was examined by studying BDNF expression in CB2xP and AM630-treated WT mice 
exposed to CMS.  
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2. MATERIALS AND METHODS 
 
2.1. Animals  
 
Male mice overexpressing CB2r (CB2xP) made in our laboratory as described previously (33) and 
their corresponding littermates (WT) mice (age 2-3 months, 25-35 g) were used in all experiments. All 
animals were maintained under controlled temperature (23±2ºC) and light (light-dark cycle from 8.00 
to 20.00 hours). All studies were performed in compliance with the Royal Decree 223/1998 of 14 
March (BOE. 8 18) and the Ministerial Order of 13 October 1989 (BOE 18) as well as with the 
European Council Directive of 24 November 1986 (86/609/EEC). 
 
2.2. Drugs 
 AM630 (6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone) 
was obtained from Tocris (Biogen, Madrid, Spain) and dissolved in DMSO:Tween 80:distilled water 
(1:1:8) immediately use (22;23). In acute experiments, drug was administered at 1 and 3 mg/kg (i.p., 
0.3 ml) 30 minutes before the corresponding experimental test. At the end of the 4-week of CMS, mice 
were assigned to different groups, so the initial coat state and body weight were equivalent in all 
groups. Drug was given twice daily (9.00 and 18.00) at 1 mg/kg (i.p., 0.3 ml) during 4 weeks. 
 
2.3. Behavioral analyses 
2.3.1. Tail suspension test  
Mice were individually suspended by the tail on the edge of a lever above the table top (distance 
from the floor was 35 cm) by using adhesive tape placed approximately 1-2 cm from the tip of the tail 
(24). The time of immobility was measured during a period of 6 minutes. In this situation, mice develop 
escape-oriented behaviors interspersed with temporally increasing bouts of immobility.  
 
2.3.2. Novelty suppressed feeding test 
The testing apparatus consisted of a transparent methacrylate square cage 40 x 40 x 50 cm (37). 
At the time of testing, a single pellet of food was placed on a white paper platform in the center of the 
cage. Mice fasted for 24 hours, were individually placed in the corner of the apparatus. The time of 
latency to initiate consumption of the pellet was recorded to a ceiling of 5 minutes. Once the mice 
started to eat, the total amount of food pellet (g) was measured during a period of 5 minutes.  
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2.3.3. Forced swimming test 
The FST has been used as a model predictive of antidepressant action (38). Briefly, each mouse 
was placed for 15 min in vertical Plexiglas cylinder (height 25 cm diameter 18 cm) containing water to 
a depth of 15 cm at 25±1 °C (25). After 24 h, animals were placed again into the cylinder and the 
duration of the immobility was measured during a period of 5 min. Only active swimming, not floating 
movements, was taken into account for immobility measurement.  
 
2.3.4. Chronic unpredictable mild stress  
Mice were exposed to CMS during a period of 7-8 weeks (26;27). Mice were subjected several 
times per day to one or more of the following stressors: wet cage, food deprivation, restraint stress, 
period of stroboscopic illumination (150 flashes/min), inversion of light/dark cycle, tilted cage (45º) and 
strong noise (90-105 db). All the stressors and/or sequences were applied at different times point to 
avoid habituation and to provide an unpredictable feature to the stressors (Table 1). 
 
2.3.5. Sucrose consumption test 
 Sucrose intake (1% sucrose solution) was measured after 18 hours of food and water deprivation 
(28). Consumption of sucrose solution was estimated simultaneously in control and experimental 
groups by comparing bottle weight before and after the 1-h window. The sucrose intake was 
expressed as mg sucrose/g body weight). 
 
2.4  Analysis of BDNF gene expression  
 Brain sections were cut at 500 μm at different levels containing the regions of interest according to 
Paxinos and Franklin (29), mounted onto slides and stored at −80 °C. Sections were dissected 
following the method described by Palkovits (30). Total RNA was obtained from brain punches using 
Biozol® Total RNA extraction reagent (Bioflux, Inilab, Madrid, Spain). After DNAse digestion, the 
reverse transcription was carried out following the instructions of the manufacturer (Epicentre, Tech. 
Corp., Madison, Wisconsin). BDNF gene expression was measured by using Taqman Gene 
Expression assay (Mm00432069_m1) (Applied Biosystems, Madrid, Spain) as a double-stranded 
DNA-specific fluorescent dye and performed on the AbbiPrism 7700 Real Time Cycler (Applied 
Biosystems, Madrid, Spain). The reference gene used was 18S rRNA, detected using Taqman 
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ribosomal RNA control reagents. Briefly, data for each target gene were normalized to the 
endogenous reference gene, and the fold change in target gene abundance was determined using the 
2-ΔΔCt method (31). 
 
2.5. Immunohistochemistry 
CB2xP and WT mice (n=3-5/group) were anesthetized with ketamine/xylacine (2:1 v/v, 0.2 ml), 
and intracardially perfused with 200 ml of 4% paraformaldehyde in phosphate buffer (PB; 0.1 M, pH 
7.4). Brains were dissected, postfixed in the same fixative solution overnight at 4 ºC, frozen and cut 
into coronal 50 μm sections using a vibratome. For CB2r, floating sections were pre-incubated with 50 
mM sodium citrate pH 9, for 30 min at 80 ºC, washed three times with phosphate-buffered saline 
(PBS; 0.1 M, pH 7.3), and then incubated with 1% hydrogen peroxide in PBS for 20 min at room 
temperature to inhibit endogenous peroxidase, washed three times with PBS, incubated for 1 h in 10% 
normal goat serum (NGS) in PBS and 0.3% triton X-100, at room temperature. Then, sections were 
incubated in primary CB2 antibody obtained from Cayman Chemicals (MI, USA), diluted 1:500 in PBS 
+ 0.3% triton X-100, overnight at room temperature, rinsed, incubated for 1 h at room temperature in 
1:500 dilution of biotinylated goat anti-rabbit secondary antibody (Vector, Burlingame, CA, USA) in 
PBS + 0.3% triton X-100, rinsed, incubated in extravidin-peroxidase (Sigma-Aldrich, Madrid, Spain) 
diluted 1:2000 in PBS + 0.2% triton X-100 for 1 h at room temperature, rinsed, and then incubated in a 
solution containing 0.05% diaminobenzidine-niquel (DAB-Ni) (Sigma-Aldrich, Madrid, Spain) and 
0.003% hydrogen peroxide for color deposition. Sections were mounted on coated slides, dehydrated, 
cover slipped, viewed and photographed using Zeiss and Leitz microscope and a Nikon digital 
camera, and images were edited using photoshop (vCS3; Adobe systems) and quantified using Image 
J software (National Institutes of Health, USA) after background subtraction.  
 For BDNF, floating sections were washed three times with PBS, and then incubated with 1% 
hydrogen peroxide in methanol:PBS (1:1) for 15 min at room temperature to inhibit endogenous 
peroxidase, washed three times with PBS + 0.2% triton X-100 (PBS-T), incubated for 1 h in 10% NGS 
in PBS-T at room temperature. Then, sections were rinsed and incubated in primary BDNF antibody 
obtained from Chemicon (Temecula, CA, USA), diluted 1:100 in PBS-T, overnight at 4 ºC, rinsed, 
incubated for 1.5 h at room temperature in 1:200 dilution of biotinylated goat anti-rabbit secondary 
antibody (Vector, Burlingame, CA, USA) in PBS-T, rinsed, incubated in extravidin-peroxidase (Sigma-
         María S. García-Gutiérrez 
 8 
Aldrich, Madrid, Spain) diluted 1:500 in PBS-T for 1.5 h at room temperature, rinsed, and then 
incubated in a solution containing 0.05% diaminobenzidine (Sigma-Aldrich, Madrid, Spain) and 
0.003% hydrogen peroxide for color deposition. Sections were mounted and analyzed as mentioned 
before. 
 
2.6. Statistical analyses 
 Statistical analyses were performed using the Student t-test when comparing two groups and one-
way or two-way analysis of variance followed by the Student Newman Keul’s test when comparing 
three or four groups. Differences were considered significant if the probability of error was less than 
5%. Data are presented as mean ± S.E.M. SigmaStat 3.1 software was used for all statistical 
analyses.   
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3. RESULTS 
 
3.1 Characterization of CB2r expression 
3.1.1 Analysis of CB2r gene expression  
 The analyses of the different brain punches in WT mice by Rt-PCR revealed the presence of CB2r 
gene expression in almost all the nuclei examined. The results were expressed considering the CPu 
as 100% (arbitrarily).  In this manner, CB2r gene expression resulted significantly higher in Acc 
(137%), Amy (107%), VMN (90%), Sn (224.62%) and MnR (84%) compared to CPu (n= 6-7/group) 
(see Table 2 and Figure 1A).  
 CB2xP mice presented significant increased CB2r mRNA levels in all the regions analyzed 
compared to WT mice (Student t-test, CPu t= -3.047, p<0.011, 11 df (150%); Acc  t= -4.590, p= 0.001, 
9 df (180%); Cg t=-6.125, p<0.001, 9 df (199%); Amy t= -1.573, p= 0.05, 9 df (64%); Hipp t= -2.464, p= 
0.027, 14 df (158%); VMN t= -2.863, p<0.001, 9 df (126%); ARC t= -2.184, p= 0.05, 9 df (157%); SN 
t= -3.36, p= 0.006, 11 df (278%); VTA t= 3.876, p= 0.003, 10 df; DR t= 2.548, p=0.031, 9 df (50%); 
MnR t= 2.987, p= 0.014, 10 df) (n= 6-7/group) (Figure 1A).  
  
3.1.2 
The results revealed increased expression of CB2 protein in different fields of hippocampus (CA2, 
CA3 and DG) in CB2xP mice compared to WT mice (Student t-test CA2 t= 5.451, p= 0.002, 6 df ; CA3 
t= 4.278, p= 0.005, 6 df; DG t= 3.937, p= 0.008, 6 df) (n= 4/group). No differences were detected in 
CA1 field (Student t-test t= 1.642, p= 0.152, 6 df) (n= 4/group) (Figure 1B and 1C). 
CB2r protein expression in the hippocampus  
 
3.2 Behavioral analyses 
 
The effects of CB2xP and WT mice to acute and chronic anxiogenic-like stimuli were evaluated by 
using TST, NSFT and CMS tests.  
CB2xP mice showed significantly less time of immobility compared to WT mice during the TST 
(Student t-test, t= 5.723, p<0.001, 20 df) (n=12-14/group) (Figure 2A).  
Accordingly, CB2xP mice presented significantly lower time of latency (Student t-test, t= 2.463, p= 
0.023, 20 df) and displayed pronounced increase in consumption of food pellets (g) compared to WT 
mice during the NSFT (Student t-test, t= -3.711, p= 0.001, 21 df) (n=11-12/group) (Figure 2B).  
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 In CMS, depressive-like behaviors were evaluated at different time points by using the TST (5 
week) and sucrose intake tests (7 week). In the TST, stressed-WT mice present significant higher time 
of immobility compared with non-stressed-WT mice (Student t-test, t= -2.664, p= 0.011, 20 df) (n= 
12/group) (Figure 2 C1, left panel). In contrast, no differences were observed between stressed and 
non-stressed-CB2xP groups (Student t-test, t= 0.644, p= 0.526, 21 df) (n= 12/group) (Figure 2 C1, 
right panel).  
 At the end of 7-weeks of CMS, stressed-WT mice presented significant reduction of sucrose intake 
(mg sucrose/g bw) compared with non-stressed-WT mice (Student t-test, t=3.151, p=0.025, 5 df) 
(n=12/group) (Figure 2 C2, left panel). Interestingly, CMS failed to produce any alteration in the 
sucrose intake of CB2xP mice (Student t-test, t= 0.365, p= 0.721, 13 df) (n= 12/group) (Figure 2 C2, 
right panel).  
  
3.3 Analysis of BDNF in CB2xP and WT mice exposed to CMS  
 The expression of BDNF in the hippocampus, especially at the dentate gyrus (DG), is known to be 
down regulated in response to chronic stress (45). In the present study, hippocampus BDNF gene 
expression of CB2xP and WT mice exposed to the CMS was measured by real-time PCR. As 
expected, stressed-WT mice presented significant reduction of BDNF gene expression compared with 
non-stressed-WT mice. In contrast, CMS failed to produce any alteration in BDNF gene expression of 
stressed-CB2xP mice. Interestingly, CB2xP mice showed significant basal higher BDNF mRNA levels 
compared to WT mice (two way ANOVA followed by Student Newman Keul’s, genotype F(1,26)= 
19.033, p<0.001; stress F(1,26)= 1.520, p= 0.230, genotype x stress F(1,26)= 0.299) (n= 5-7/group) 
(Figure 3 A1).  
 BDNF protein expression was significantly reduced in the DG of stressed-WT compared to non-
stressed-WT mice. In contrast, no alterations were found in CB2xP mice (two way ANOVA followed by 
Student Newman Keul’s, genotype F(1,32)= 4.192, p= 0.050; stress F(1,32)= 3.355, p= 0.077, genotype x 
stress F(1,32)
The effects of acute administration of AM630 on the response to anxiogenic-like stimuli were 
evaluated in CB2xP and WT mice by using the FST. The results revealed that AM630 increases 
= 7.381, p= 0.011) (n= 5-6/group) (Figure 3 A2 and A3).  
 
 
3.4 Acute and chronic effects of cannabinoid CB2 r antagonist  
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significantly the time of immobility in WT mice at 1 and 3 mg/kg (one way ANOVA F(2,18)= 15.506, 
p<0.001) (n= 7-9 per group) (Figure 4A, left panels). In contrast, this drug failed to produce any 
change in CB2xP mice (one way ANOVA F(2,12)= 0.120, p= 0.888) (n= 6-8/group) (Figure 4A, right 
panels). 
 In addition, the effects of chronic administration of AM630 on the response to anxiogenic-like 
stimuli were evaluated in WT mice exposed to CMS. Before administration of AM630, depressive-like 
behaviors were corroborated at different time points during CMS by using the TST (3rd week) and 
sucrose intake (4th week). The results revealed significant increased time of immobility in stressed-
WT compared with non-stressed-WT mice (Student t-test, t= -2.664, p= 0.011, 38 df) (n= 24/group) 
(Figure 4 B1). In addition, sucrose intake was significantly reduced in stressed-WT (Student t-test, t= 
4.766, p= 0.009, 4 df) (n= 24/group) (Figure 4 B2). These results support that the stressful 
manipulations carried out during CMS are indeed causing depressive-like behaviors.  
 Once CMS was established, the chronic treatment with AM630 started. On weeks 3 and 4 after the 
initiation of the treatment, depressive-like behaviors were evaluated by using TST and sucrose intake 
test, respectively. As expected, vehicle stressed-WT mice presented increased time of immobility 
compared with vehicle non-stressed-WT mice. In contrast, no differences were found between AM630 
stressed-WT mice and vehicle non-stressed-WT mice. In addition, the administration of AM630 failed 
to produce any alteration in non-stressed-WT mice  (Two-way ANOVA followed by Student Newman 
Keul’s stress F(1,30)= 1.562, p= 0.222; drug F(1,30)= 1.879, p= 0.182; stress x drug F(1,30)= 4.358, p= 
0.046) (n=9-11/group) (Figure 4 B3).  
 On week 4, vehicle stressed-WT mice presented significant reduction of sucrose intake compared 
to vehicle non-stressed-WT mice. In contrast, stressed mice treated with AM630 did not show 
differences in the sucrose intake compared with non-stressed-WT mice. On the other hand, the 
administration of AM630 failed to produce any alteration in non-stressed-WT mice (Two way ANOVA 
followed by Student Newman Keul’s stress F(1,21)= 42.042, p<0.001; drug F(1,21)= 13.395, p=0.002; 
drug x genotype F(1,21)= 31.908, p<0.001) (n= 9-11/group) (Figure 4 B4). These results suggest that 4-
weeks AM630 treatment was appropriated to achieve a significant improvement in depressive-like 
behaviors.  
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3.5 Analysis of BDNF expression in CB2xP and WT mice exposed to the CMS procedure and treated 
with AM630  
 BDNF gene expression was significantly reduced in vehicle stressed-WT compared with vehicle 
non-stressed-WT mice. In contrast, treatment with AM630 significantly blocked the reduction of BDNF 
mRNA levels induced by CMS procedure compared to vehicle stressed group. Interestingly, 
administration of AM630 by itself failed to produce any alteration in BDNF gene expression (two way 
ANOVA followed by Student Newman Keul’s, stress F(1,26)= 4.931, p=0.037; drug F(1,26)= 40.393, 
p<0.001, stress x drug F(1,26)= 17.310, p<0.001 ) (n= 10-12/group) (Figure 5 A1).  
 In agreement with these results, BDNF protein expression was reduced in DG of vehicle stressed 
and vehicle non-stressed-WT mice. In addition, the administration of AM630 completely blocked the 
reduction of BDNF protein levels induced by CMS. AM630 administration alone failed to produce any 
alteration in BDNF protein (two way ANOVA followed by Student Newman Keul’s, stress F(1,35)= 1.913, 
p= 0.176; drug F(1,35)= 13.148, p<0.001, stress x drug F(1,35)= 17.656, p<0.001) (n= 5-6/group) (Figure 
5 A2 and A3).  
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4. DISCUSSION 
The results of the present study provide unequivocal information involving the CB2r in the 
regulation of depressive-like behaviors. This assumption is supported by several facts: 1) The 
presence of basal CB2r gene expression in areas related to stress and depression in WT mice, 2) The 
overexpression of CB2r produced a behavioral endophenotype resistant to acute and chronic 
anxiogenic-like stimuli, 3) CB2xP mice presented higher BDNF gene expression in the hippocampus 
and 4) Treatment with AM630 blocked or significantly reduced signs of depressive-like behavior and 
BDNF loss in the hippocampus after chronic exposure to anxiogenic-like stimuli in WT mice.   
This study describes for the first time the distribution of CB2r gene expression in different brain 
nuclei of WT mice under normal conditions (CPu, Acc, Cg, Amy, Hipp, VMN, ARC, SN, DR and MnR). 
The identification of CB2r gene expression in these brain regions predicts the role of these receptors 
in a wide variety of physiological functions. For instance, functional expression of these receptors in 
areas related to stress, anxiety and depression, such as Amy, Hipp, DR and MnR, further supports its 
potential role in the regulation of anxiety and depressive-like disorders. 
To evaluate the implication of CB2r in the regulation of depressive-like behavior CB2xP mice were 
used in a variety of experimental paradigms. Previous studies evaluating the role of this receptor in the 
regulation of neuropathic pain have partially described these transgenic CB2xP mice (32-33). In the 
present study, CB2r gene expression was enhanced in the different brain nuclei analyzed (CPu, Acc, 
Cg, Amy, Hipp, VMN, ARC, SN, DR and MnR) of CB2xP mice. Furthermore, a significant increase of 
CB2r protein in the DG, CA3 and CA2 of hippocampus was also found in CB2xP mice.  
The results of the analyses in the TST and NSFT revealed that CB2xP mice display a behavioral 
endophenotype resistant to acute anxiogenic-like stimulus. This response was characterized by 
decreased time of immobility, lower time of latency and higher amount of food consumption of CB2xP 
mice in TST and NSFT, respectively.  
The effects of chronic anxiogenic-stimuli were examined exposing CB2xP mice to CMS. This 
animal model of depression involves the presentation of repeated unpredictable mild stressors for 
several weeks (34-35). Following such exposure, animals exhibited a persistent reduction in the 
responsiveness to pleasurable stimuli such as a palatable sucrose solution (36-38). CMS produced 
depressive-like behavioral alterations in WT mice (reduced time of immobility in TST and sucrose 
intake). In contrast, exposure to CMS failed to produce any alteration in CB2xP mice. Interestingly, 
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CB2xP mice (under basal conditions) presented higher sucrose intake levels than WT mice. Although 
the precise mechanisms underlying these basal differences remain to be elucidated, it is tempting to 
speculate that CB2xP mice may present neuroendocrine and/or peripheral alterations that may be 
disrupting the homeostatic regulation of glucose, therefore modifying the appetite of these mice.  
Exposure to CMS decreased neurogenesis and produced alterations of the remodeling dendrites 
process in hippocampus (39-42). In this respect, BDNF plays an important role in adult neurogenesis 
modulating plasticity and survival of adult neurons and glia cells (43). Converging evidences revealed 
a reduction of hippocampal BDNF in rodents exposed to CMS (28;44-45). Moreover, clinical studies 
showed a reduction of hippocampal neurogenesis in patients with mood disorders (46-47). In 
agreement with these findings, the results of this study revealed that CMS reduced hippocampal 
BDNF gene and protein expressions in stressed-WT mice. In contrast, CMS failed to produce any 
alteration in BDNF gene and protein expressions in CB2xP mice. Indeed, CB2xP mice presented 
higher BDNF gene expression in the hippocampus than WT mice. The nature of the precise molecular 
alterations produced in CB2xP mice is still unknown. However, these findings point the CB2r as an 
important target involved in the “normalization” of the reduced BDNF expression in the hippocampus 
of mice exposed to CMS. 
If overexpression of CB2r produces molecular adaptations that are associated with an 
endophenotype resistant to acute and chronic anxiogenic-like stimuli, it is possible to hypothesize that 
pharmacological manipulation with a cannabinoid CB2 antagonist (which treatment would probably 
increase the number of CB2r (48-49)) would produce similar effects in WT mice. In order to explore 
this hypothesis, the effects of AM630 were assessed in different behavioral paradigms.   
The administration of AM630 (1 and 3 mg/kg) reduced the time of immobility (FST) in WT mice. 
These doses were without effects on the motor activity of WT mice in the open-field test (data not 
shown).  Interestingly, the administration of AM630 did not alter the time of immobility in CB2xP mice 
at any of the tested doses. It is possible to propose that the lack of effects of AM630 in CB2xP mice 
was due to the increased expression of CB2r in these mice.  
The effects of chronic (4 weeks) administration with AM630 reversed the reduction of immobility 
time in the TST and the decrease of sucrose intake, both induced by CMS. Furthermore, this 
treatment significantly blocked the reduction of BDNF gene and protein expressions in the 
hippocampus observed in CMS. Interestingly, the administration of AM630 increased BDNF gene 
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expression in the stressed mice although this alteration was not occurring at the level of protein. The 
reasons that may explain why the blockade of CB2r increased BDNF gene expression only in 
chronically stressed mice are still unknown. It can be hypothesized that AM630 act in a different 
manner depending on the level of activity of BDNF and CB2r. Under basal conditions (non-stress) the 
blockade of the receptor is not affecting the homeostatic regulation between CB2r and BDNF. In 
contrast, CMS would presumably increases the release of endogenous cannabinoid ligands, which in 
turn, could tend to down regulate CB2r and decreased BDNF expression. These changes may result 
in hypersensitization of the CB2r, and through an unknown mechanism, could be responsible of the 
pronounced increase of BDNF after treatment with AM630. Further studies are needed to identify the 
precise neurochemical mechanisms by which the CB2r regulates BDNF gene expression during 
stress. 
In summary, the results presented here show that CB2r play a pivotal role in the neurobiology of 
depressive related disorders. Overexpression of CB2r resulted in a behavioral endophenotype 
resistant to anxiogenic-like stimulus and modified  different targets involved in the neuroplasticity of 
depressive disorders, such as BDNF. In addition, the acute and chronic treatment with AM630 
resulted in antidepressant-like effects and reversed the reduction of BDNF induced in the 
hippocampus of mice exposed to CMS. Taken together, these findings strongly support the role of 
CB2r in the regulation of depressive disorders and point out this receptor as a new potential key target 
in the treatment of different mood-related disorders.  
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FIGURE LEGENDS 
 
Figure 1. CB2 receptor gene expression in CB2xP and WT mice. A) Relative CB2 receptor gene 
expression in different brain nuclei of CB2xP and WT mice by Rt-PCR (CPu: caudate-putamen 
nucleus, Acc: nucleus accumbens, Cg: Cingulated cortex, Amy: Amygdala, Hipp: hippocampus, VMN: 
ventromedial nucleus of hypothalamus, ARC: arcuate nucleus of hypothalamus, Sn: substantia nigra, 
VTA: ventral tegmental area; DR: dorsal raphe, MnR: medial raphe). Relative expression was 
calculated according to the ∆∆Ct method. Columns represent the means and vertical lines the ± SEM 
of relative CB2 gene expression, * Values from different brain WT mice regions that are significantly 
different from CPu WT mice, & Values from CB2xP mice (black columns) in each brain region that are 
significantly different (p<0.05, Student t-test) compared to its corresponding region of WT mice (white 
columns) (n= 6-7 per group). B) CB2 receptor immunostaining in different fields of hippocampus in 
CB2xP and WT mice. DG: Dentate gyrus. * Values from CB2xP mice (black columns) that are 
significantly different (p<0.05, Student t-test) from WT mice (white columns) (n= 4 per group). C) 
Representative autoradiograms for CB2 protein in hippocampus of WT and CB2xP mice; bar 
represent 1 mm.  
 
 
Figure 2. Assessment of depressive-like behaviors in CB2xP and WT mice in tail suspension (A), 
novelty suppressed feeding (B) and chronic unpredictable mild stress paradigms (C). Columns 
represent the means and vertical lines ± SEM of A (time of immobility (s)) and B (time of latency (s) 
and (consumption of food pellets (g)) in 11-14 mice; * Values from CB2xP mice (black columns) that 
are significantly different from WT mice (white columns) (p<0.05, Student t-test). During the CMS 
procedure, depressive-like behaviors were evaluated by using tail suspension (5 week) (C2) and 
sucrose intake tests (7 week) (C3) (n= 12) (See methods). Columns represent the means and vertical 
lines ± SEM of time of latency (s) (C2) and sucrose intake (mg sacarose/g body weight) (C3) (n= 12-
16 mice per group). & Values from stressed-WT mice that are significantly different from non-stressed 
WT mice (p<0.05, Student t-test).  Bw: Body weight.  
 
 
 
 
 
         María S. García-Gutiérrez 
 21 
 
 
 
Figure 3. BDNF gene and protein expressions in CB2xP and WT mice exposed to CMS.  A1) Relative 
BDNF mRNA levels in hippocampus of CB2xP and WT mice exposed to CMS. Columns represent the 
means and vertical lines the ± SEM of relative BDNF mRNA gene expression, * Values from non-
stressed-WT, stressed-CB2xP and non-stressed-CB2xP mice that are significantly different from non-
stressed-WT group (two way ANOVA, followed by Student Newman Keul’s, p<0.05) (n=5-7 per group). 
A2) Quantification of BDNF immunostaning in hippocampus of CB2xP and WT mice exposed to CMS. 
Columns represent the means and vertical lines the ± SEM of relative BDNF protein (arbritrary units). * 
Values from stressed-WT mice that are significantly different from non-stressed-WT mice (two way 
ANOVA, followed by Student Newman Keul’s, p<0.05) (n= 5-6 per group).  A3) Representative 
autoradiograms for BDNF protein in hippocampus of CB2xP and WT mice exposed to CMS. Bar 
represent 1 mm. 
 
 
Figure 4. Acute and chronic effects of cannabinoid CB2 antagonist AM630 treatment. A) Dose-
response effects of AM630 on forced swimming test in WT and CB2xP mice. Columns represent the 
means and vertical lines the ± SEM of time of immobility (s). * Values from AM630-WT group (1 and 3 
mg/kg, i.p.) that are significantly different from vehicle-WT group (one way ANOVA followed by 
Student Newman Keul’s, p<0.05) (n=6-8). B) Chronic effects of AM630 treatment in WT mice exposed 
to CMS paradigm. Evaluation of depressive-like behaviors on weeks 3 and 4 of the CMS paradigm by 
using tail suspension (B1) and sucrose intake (B2) tests, respectively (n= 24). Evaluation of 
depressive-like behaviors on weeks 3 and 4 after chronic AM630 treatment by using tail suspension 
(B3) and sucrose intake (B4) tests, respectively (n= 9-11) (see methods).  Columns represent the 
means and vertical lines the ± SEM of time of immobility (s) (B1, B3) and sucrose intake (mg sucrose/ 
g body weight) (B2, B4). * Values from stress-WT group that are significantly different from non-
stressed-WT group (two way ANOVA followed Studen’t Newman Keul’s, p<0.05), # Values from 
vehicle stressed-WT group that are significantly different from from vehicle non-stressed-WT group 
(two way ANOVA followed Studen’t Newman Keul’s, p<0.05). Bw: Body weight.  
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Figure 5. BDNF gene and protein expressions in chronic AM630 treated WT mice exposed to CMS.  
A1) Relative BDNF mRNA levels in hippocampus of AM630 and vehicle WT mice exposed to CMS. 
Columns represent the means and vertical lines the ± SEM of relative BDNF mRNA gene expression, 
* Values from vehicle stressed-WT and AM630 stressed-WT groups that are significantly different from 
vehicle non-stressed-WT group (two way ANOVA, followed by Student Newman Keul’s, p<0.05) (n= 
10-11 per group). A2) BDNF immunostaining in the hippocampus of AM630 and vehicle WT mice 
exposed to CMS. Columns represent the means and vertical lines the ± SEM of relative BDNF protein 
(arbritrary units). * Values from vehicle stressed-WT group that are significantly different from vehicle 
non-stressed-WT group (two way ANOVA, followed by Student Newman Keul’s, p<0.05) (n= 5-6 per 
group). A3) Representative autoradiograms for BDNF protein in hippocampus WT stressed and non-
stressed AM630 and vehicle mice. Bar represent 1 mm. 
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Table 1. Chronic unpredictable mild stress procedure 
 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Week 
1 
10-12h Strong noise  
14-17h Stroboscopic 
illumination                    
18-19h Restraint 
stress 
10-11h Restraint 
stress     14-16h 
Strong noise          19-
8.30h Food 
deprivation  
10-13.30h 
Stroboscopic 
illumination                                
16-17h Restraint 
stress            19-8.30h 
Tilted cage                 
10-11h Restraint 
stress                      
14-16h Strong noise    
19-8.30h Wet cage        
10-13h Stroboscopic 
illumination    
16-17h Restraint 
stress 
19-19h Tilted cage                                               
 
 
 
19-8.30h Food 
deprivation  
8.30-8.30h Inversion 
light/dark cycle 
Week 
2 
10-11h Restraint 
stress  14-17h 
Stroboscopic 
illumination                  
19-8.30h Wet cage                                               
10-13.30h 
Stroboscopic 
illumination                   
16-17h Restraint 
stress 19-8.30h Tilted
cage                                                       
10-12h Strong noise    
14-17h Stroboscopic 
illumination                  
18-19h Restraint 
stress        
8.30-13h Behavioural 
test= Light-Dark box  
15-17h Strong noise    
18-19h Restraint 
stress 
10-13.30h 
Stroboscopic 
illumination    
 
19-8.30h Food 
deprivation                 
8.30-19h Inversion 
light/dark cycle 
 
 
 
19-8.30h Wet cage        
Week 
3 
10-12h Strong noise     
14.30-15.30h 
Restraint stress   
19-8.30h Tilted cage                          
10-11h Restraint 
stress 
14-17h Stroboscopic 
illumination                 
17.30-19.30h Strong 
noise 
10-12h Strong noise   
14-15h Restraint 
stress 
 
19-8.30h Food 
deprivation 
8.30-13h Behavioural 
test= Elevated Plus 
Maze 
15-18h Stroboscopic 
illumination                     
19-8.30h Wet cage        
10-13.30h 
Stroboscopic 
illumination                  
15-16h Restraint 
stress 17-19h Strong 
noise 
8.30-19h Inversion 
light/dark cycle 
 
 
 
19-8.30h Food 
deprivation                 
Week 
4 
8.30-13h Behavioural 
test= Tail Suspension 
Test                              
14-16h Strong noise    
18-19h Restraint 
stress           
10-13.30h 
Stroboscopic 
illumination                  
16-17h Restraint 
stress  19-8.30h Tilted 
cage                                                                    
10-11h Restraint 
stress  14-17h 
Stroboscopic 
illumination                  
19-8.30h Wet cage                             
10-12h Strong noise    
15-18h Stroboscopic 
illumination                     
10-12h Strong noise    
16-17h Restraint 
stress  19-19h Tilted 
cage                                               
 
 
19-8.30h Food 
deprivation 
8.30-8.30h Inversion 
light/dark cycle 
Week 
5 
10-11h Restraint 
stress  14-16h Strong 
noise       
19-8.30h Wet cage                 
11-14.30h 
Stroboscopic 
illumination                                 
16-18h  Strong noise       
10-11h Restraint 
stress 
14-16h Strong noise    
19-8.30h Tilted cage                      
11-14.30h 
Stroboscopic 
illumination                                 
16-17h Restraint 
stress 19-8.30h Wet 
cage                     
10-12h Strong noise     
14-17h Stroboscopic 
illumination   
18-19h  Restraint 
stress                  
8.30-18.00h Tilted 
cage                      
 
19-8.30h Food 
deprivation 
8.30-8.30h Inversion 
light/dark cycle 
Week 
6 
10-12h Strong noise 
16-17h Restraint 
stress 19-8.30h Wet 
cage                       
 
10-13.30h 
Stroboscopic 
illumination                  
16-17h Restraint 
stress 19-8.30h Tilted 
cage                                         
10-12h Strong noise   
14-15h Restraint 
stress 
19-8.30h Food 
deprivation 
10-11h Restraint 
stress                      
14-16h Strong noise     
19-13h Food and 
water deprivation  
13-14h Behavioural 
test= Sucrose Intake  
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     Table 2.  CB2 gene expression (relative to CPu) in WT mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REGIONS Student t-test 
Acc t= -3.099, p<0.011, 10 df * (137%) 
Cg t= -0.688, p<0.505, 11 df 
Amy t= -2.410, p<0.037, 10 df * (107%) 
Hipp t= -0.226, p<0.825, 13 df 
VMN t=-2.849, p<0.017, 10 df * (90%) 
ARC t= -1.847, p<0.092, 11 df 
Sn t= -3.125, p<0.010, 11 df * (224%) 
VTA Non detected 
DR t= -0.568, p=0.582, 10 df 
MnR t= -2.190, p=0.050, 11 df * (84%) 
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